We compared the background characteristics of patients with chronic hepatitis C who achieved eradication of hepatitis C virus (HCV), that is sustained virologic response (SVR), with interferon (IFN)-based versus IFN-free antiviral therapy in Japan. In addition, we used a previously reported risk assessment model to compare the incidence of hepatocellular carcinoma (HCC) after SVR by treatment type. Pretreatment characteristics of 1533 patients who achieved SVR with IFN-based therapy and 1086 patients with IFN-free therapy from five institutions across Japan were compared. The risk of HCC after SVR was assessed based on pretreatment characteristics, and the incidence of HCC after SVR was estimated in both groups. Age and serum alpha-fetoprotein levels were higher, platelet count was lower, and liver fibrosis was more advanced in patients who achieved SVR with IFN-free therapy compared with IFN-based therapy. The incidence of HCC after SVR in the IFN-free group was estimated to be more than twofold higher than in the IFN-based therapy group (7.29% vs. 3.09%, and 6.23% vs. 3.01% when excluding patients who have underwent curative treatment for HCC). There are large differences in pretreatment characteristics between patients who achieved SVR with IFN-based and IFN-free therapies in Japan, which are associated with differential risk of HCC after SVR. These differences can influence the incidence of HCC after SVR and should be taken into consideration when comparing IFN-based and IFN-free therapies in terms of hepatocarcinogenesis suppression with HCV eradication.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jvh.12665 | DOI Listing |
Clin Infect Dis
January 2025
Veteran Affairs Portland Health Care System, Portland, OR, USA.
Background: Chronic hepatitis C virus (HCV) infection affects >1% of the U.S. population, higher among U.
View Article and Find Full Text PDFLiver Int
February 2025
Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Aliment Pharmacol Ther
January 2025
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Liver Int
February 2025
Italian Liver Cancer (ITA.LI.CA) Association, Bologna, Italy.
Background And Aims: Presence of active hepatitis C virus (HCV) infection may influence the outcome of patients treated for hepatocellular carcinoma (HCC), although this issue has never been adequately assessed in a large series of patients. The aim of this study was to evaluate whether the presence of active HCV affects the survival of patients treated for HCC.
Methods: This study assessed the outcome of 3123 anti-HCV-positive patients with HCC, subdivided according to the presence of active HCV infection or previous sustained virological response (SVR).
Aliment Pharmacol Ther
January 2025
Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!